Intra-Cellular Therapies v. Alkem: ANDA Patent Dispute Consolidated in NJ
What would you like to do next?
Choose your path based on your current needs in pharmaceutical IP:
📋 Case Summary
| Case Name | Intra-Cellular Therapies, Inc. v. Alkem Laboratories, Ltd. |
| Case Number | 3:24-cv-10234 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Nov 2024 – Jan 2025 70 days |
| Outcome | Procedural Closure – Consolidation |
| Patents at Issue | |
| Accused Products | Lumateperone Capsules (10.5 mg, 21 mg, and 42 mg) |
Case Overview
The Parties
⚖️ Plaintiff
A biopharmaceutical company focused on central nervous system (CNS) disorders, ITCI developed and commercializes CAPLYTA® (lumateperone).
🛡️ Defendant
A major India-based generic pharmaceutical manufacturer with significant U.S. market presence through ANDA filings for various drugs.
The Patents at Issue
This case involved three recently issued U.S. patents protecting CAPLYTA® (lumateperone) capsules, which provide layered pharmaceutical patent protection:
- • U.S. Patent No. 12,128,043 B2 — Formulation and/or method-of-use aspects of lumateperone.
- • U.S. Patent No. 12,122,792 B2 — Formulation and/or method-of-use aspects of lumateperone.
- • U.S. Patent No. 12,090,155 B2 — Formulation and/or method-of-use aspects of lumateperone.
Developing a generic drug?
Check if your lumateperone formulation might infringe these or related patents.
Litigation Timeline & Procedural History
The litigation trajectory of Case No. 3:24-cv-10234 is best understood within ITCI’s broader, coordinated multi-defendant enforcement strategy:
- • **March 27–28, 2024:** ITCI filed initial ANDA infringement actions against Aurobindo, Alkem, DRL, Hetero, MSN, Sandoz, and Zydus.
- • **August 29, 2024:** ITCI filed a second wave of related civil actions against the same seven defendants, asserting newly issued patents.
- • **November 1, 2024:** Case No. 3:24-cv-10234 was filed against Alkem, asserting the three patents analyzed here.
- • **January 10, 2025:** The case closed—consolidated into the lead docket (Civil Action No. 3:24-cv-04264)—after just **70 days**.
The District of New Jersey is a preeminent venue for Hatch-Waxman ANDA litigation, offering judges experienced in pharmaceutical patent disputes. The 70-day duration reflects a consolidation outcome rather than substantive adjudication, meaning the merits will be litigated under the consolidated lead case.
The Verdict & Legal Analysis
Outcome
Case No. 3:24-cv-10234 was **closed on the basis of consolidation** — specifically, it was merged into the lead consolidated action (Civil Action No. 3:24-cv-04264) already encompassing ITCI’s claims against Aurobindo, Alkem, DRL, Hetero, MSN, Sandoz, and Zydus. No damages were awarded and no injunctive relief was issued in this individual docket; those determinations remain pending in the consolidated proceeding.
Legal Significance
The closure was administrative and procedural rather than adjudicative. ITCI’s filing of this separate November 2024 action against Alkem — the third wave targeting the same defendant — reflects the mechanics of Hatch-Waxman patent listing and litigation timing. Consolidation before the same district court judge ensures consistent claim construction, coordinated discovery, and unified trial management — all strategically favorable to ITCI as the patent holder. This case exemplifies the **staggered patent listing and successive ANDA litigation model** increasingly employed by pharmaceutical innovators.
Filing new pharma patents?
Learn from this case. Use AI to draft stronger claims that can withstand ANDA litigation.
Power Your Pharmaceutical Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the complex pharmaceutical patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis for Lumateperone
This case highlights critical IP risks in generic pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this ANDA litigation.
- View all related lumateperone patents
- See which companies are most active in CNS patents
- Understand ANDA claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your generic lumateperone or similar CNS drug.
- Input your product description or technical features
- AI identifies potentially blocking pharma patents
- Get actionable risk assessment report
High Risk Area
Lumateperone capsule formulations and methods
3 Patents Asserted
Protecting CAPLYTA® (lumateperone)
Design-Around Options
Possible for formulation/method claims
✅ Key Takeaways
For Patent Attorneys & Litigators
Successive ANDA litigation filings are procedurally required when new Orange Book patents issue post-ANDA filing; consolidation is the standard resolution.
Search related case law →New Jersey District Court remains the strategic venue of choice for Hatch-Waxman multi-defendant actions.
Explore precedents →Continuation patent prosecution synchronized with commercial product lifecycle is a core branded pharma litigation tool.
Try AI patent drafting →For IP Professionals
Monitor Orange Book patent listings for ANDA-challenged products continuously — new listings trigger fresh litigation timelines.
Start FTO analysis for my product →Consolidated dockets create unified claim construction outcomes binding all generic defendants simultaneously.
Explore patent landscape →For R&D Leaders
Conduct rolling FTO assessments for ANDA products throughout development; post-filing patent issuances carry litigation risk equivalent to pre-filing patents.
Start FTO analysis for my product →Formulation differentiation from branded reference listed drug (RLD) specifications remains a primary non-infringement strategy.
Explore competitor products →Ready to Strengthen Your Pharmaceutical Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes in the pharma industry.